Maxim Group Initiates Coverage On Virios Therapeutics with Buy Rating, Announces Price Target of $1
Portfolio Pulse from Benzinga Newsdesk
Maxim Group has initiated coverage on Virios Therapeutics (NASDAQ:VIRI) with a Buy rating and set a price target of $1.
June 20, 2024 | 11:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Maxim Group has initiated coverage on Virios Therapeutics with a Buy rating and a price target of $1.
The initiation of coverage with a Buy rating and a specific price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100